FDA rejects Alnylam's Onpattro label expansion after adcomm voted in favor - Endpoints News
endpts.comSubmitted by endpointsnews6292 in news
The FDA has rejected Alnylam Pharmaceuticals’ expansion plans for its siRNA injection Onpattro, serving a complete response letter for the treatment of ATTR cardiomyopathy. The Monday morning surprise no-go comes weeks after the agency’s panel of outside advi…